BioCentury
ARTICLE | Company News

Shire to acquire Orphan company Lotus Tissue Repair

January 9, 2013 1:24 AM UTC

Shire plc (LSE:SHP; NASDAQ:SHPG) will acquire Lotus Tissue Repair Inc. (Cambridge, Mass.) for an undisclosed upfront payment, plus milestones. Shire will gain Lotus Tissue's lead product, a preclinical recombinant form of human collagen Type VII (rC7) in development as an IV protein replacement therapy to treat dystrophic epidermolysis bullosa (DEB), a rare genetic disease where the skin and other body surfaces can develop deep blisters. Shire was up a 49.20p to 1,963p on Tuesday. On NASDAQ, the stock was up $2.53 to $95.48. ...